Funding Opportunity RFA-ES-22-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports Phase I (R43), Phase II (R44), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant applications from small businesses concerns (SBCs) to develop resources and approaches, including panels of cells or model organisms, that reflect the variability in human populations in chemical toxicity testing . Current toxicology testing is often limited to studies conducted in a small number of laboratory rodent strains, which can fail to identify clinically relevant toxicity if the conventional rodent strain is particularly resistant to the toxic effects of the test compound. Cost-effective screening systems with appropriate throughput are needed to better capture this variability in responses to chemical exposure in the population based on individual genetic susceptibility.

Notice NOT-OD-22-159 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-163 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-23-018 from the NIH Guide for Grants and Contracts. To ensure that digital therapeutics that have been or are in the development for SUD are adopted, this funding opportunity concept aims to fund clinical trials that will generate convincing data to improve adoption by the payors.

Notice NOT-OD-22-162 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-161 from the NIH Guide for Grants and Contracts

Notice NOT-HS-22-018 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-171 from the NIH Guide for Grants and Contracts. The NIDDK Central Repositories house valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at https://repository.niddk.nih.gov. Applicants must provide a report from the NIDDK Central Repositories documenting sample availability.

Notice NOT-OD-22-164 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-201 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) announces the availability of support for collaborative research by multi-disciplinary teams which is of high priority to NIDA and leads to synergistic outcomes based on the synthesis of multiple research approaches. The NIDA Program Projects funding opportunity will support research in which the funding of three or more highly meritorious projects as a group enriches both the component projects and the overall program to offer significant scientific advantages over supporting the same projects as individual research grants (i.e., synergy). For the duration of the award, each Program must consist of a minimum of three research projects focused on issues critical to advance the mission and goals of NIDA.

Notice NOT-MD-22-020 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AR-23-001 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to solicit applications for Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers. These Centers promote collaborative basic, translational, and clinical research, and provide important resources that can be used by the national muscular dystrophy research community. The Centers also provide outstanding environments for the training of new scientists electing to pursue careers conducting research in high priority areas of muscular dystrophy. Furthermore, Center investigators participate in community outreach efforts to increase awareness and convey the importance and implications of their research activities to the patient and advocacy communities.

Notice NOT-EB-22-007 from the NIH Guide for Grants and Contracts

Notice NOT-HD-22-025 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-TR-22-030 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to solicit applications for pilot projects to elucidate a role for understudied proteins associated with rare diseases. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s).

Funding Opportunity RFA-OH-22-005 from the NIH Guide for Grants and Contracts. The purpose of this announcement is to provide funding to individuals in academia, members of non-profit organizations and businesses involved in fishing and maritime matters, and other entities with expertise in commercial fishing safety.

Funding Opportunity RFA-OH-22-006 from the NIH Guide for Grants and Contracts. The purpose of this announcement is to provide funding to municipalities, port authorities, other appropriate public entities, not-for-profit organizations, and other qualified persons to conduct commercial fishing vessel safety training for vessel operators and crewmembers.

Notice NOT-HG-22-028 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-22-050 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support computational dynamic modeling of molecular complexes regulating the HIV life cycle, immune responses, and therapeutic interventions in HIV/AIDS using existing and new HIV and HIV/host cell structural datasets.

Funding Opportunity PAR-22-208 from the NIH Guide for Grants and Contracts. The purpose of the FOA is to support the structural characterization of protein species associated with Alzheimer's Disease Related Dementias (ADRDs) through the utilization of cryo-electron microscopy (cryo-EM) and cryo-electron tomography (cryo-ET) of proteins expressed in human tissue and cell sources. Studies in response to this RFA should also include the development of research tools and resources to further characterize/validate the protein species. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2019 update to the National Plan to Address Alzheimer's Disease.